Receive monthly emails about the latest oncology research and technology, new patient services, resources and more!

Please select an option below to help us tailor your newsletter to best suit your content interests!

No thanks
MELANOMA: 2nd line: PD-1 + HSV-virus: RPL-001-16

An open-label, multicenter, Phase 1/2 study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors

Title
Replimune RPL-001-16 (Melanoma)
Study Title

An open-label, multicenter, Phase 1/2 study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors

Site Link
Malignancy
Melanoma, Skin Cancer, ocular melanoma, mucosal melanoma
Stage
Disease Setting
Metastatic/Palliative
Line Of Therapy
2nd
Investigational Agent
RP1 + nivolumab
Drug Class
Oncolytic virus
PI
Ari VanderWalde, MD
Sponsor
Replimune Inc.
Phase
Status
Key Eligibility Criteria
Key Eligibility Criteria Details
  • Stage IIIB-IV melanoma, following progression on PD-1 containing regimen
  • ECOG PS 0-1
  • At least one injectable tumor (visceral or deep nodal lesions may be injectable)
  • Measruable disease by RECIST 1.1
  • No prior oncolytic virus therapy (no prior T-VEC)
  • No active CNS disease
  • No history of major autoimmune disease
  • No known HBV, HCV, or HIV
  • No need for steroids >20mg prednisone daily or equivalent
  • No need for chronic use of anti-virals (e.g. acyclovir)
  • No prior malignancy in past 3 years except locally curable cancers such as non-melanoma skin cancer, or carcinoma in situ.
Objective

Primary- Safety

Secondary- Biologic activity, CR rate, DoR, PFS

Assessment Frequency
_
Assessment Frequency 2
_



Assessment Frequency Link
Path
Melanoma
Dosing Frequency
Control Agents
Study Protocol
Randomized
No
X